Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.

Animals Humans Male Molecular Targeted Therapy Prostatic Neoplasms / pathology Prostatic Neoplasms, Castration-Resistant / pathology
biomarkers cancer immunotherapy molecular imaging therapeutics tumor genomics

Journal

The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368

Informations de publication

Date de publication:
02 2019
Historique:
received: 03 10 2018
accepted: 05 10 2018
pubmed: 2 11 2018
medline: 16 11 2019
entrez: 2 11 2018
Statut: ppublish

Résumé

The 2018 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Tumor Cell Heterogeneity and Resistance," was held in Los Angeles, California from June 21 to 24, 2018. The CHPCA Meeting is a unique, discussion-oriented scientific conference convened annually by the Prostate Cancer Foundation (PCF), which focuses on the most critical topics in need of further study to advance the treatment of lethal prostate cancer. The 6th Annual CHPCA Meeting was attended by 70 investigators and concentrated on prostate cancer heterogeneity and treatment resistance. The meeting focused on topics including: recognition of tumor heterogeneity, molecular drivers of heterogeneity, the role of the tumor microenvironment, the role of heterogeneity in disease progression, metastasis and treatment resistance, clinical trials designed to target resistance and tumor heterogeneity, and immunotherapeutic approaches to target and overcome tumor heterogeneity. This review article summarizes the presentations and discussions from the 2018 CHPCA Meeting in order to share this knowledge with the scientific community and encourage new studies that will lead to improved treatments and outcomes for men with prostate cancer.

Identifiants

DOI: 10.1002/pros.23729 PMID: 30381857
pubmed: 30381857
doi: 10.1002/pros.23729
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-258

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Andrea K Miyahira (AK)

Prostate Cancer Foundation, Santa Monica, California.
ORCID: 0000-0003-4976-002X

Robert B Den (RB)

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.

Maria I Carlo (MI)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Renée de Leeuw (R)

Department of Pathology, College of Medicine, University of Illinois at Chicago, Chicago, Illinois.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
Department of Radiology, San Francisco VA Medical Center, San Francisco, California.
UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Fatima Karzai (F)

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Rana R McKay (RR)

Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California.

Simpa S Salami (SS)

Department of Urology, University of Michigan Health System, Ann Arbor, Michigan.
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.

Jonathan W Simons (JW)

Prostate Cancer Foundation, Santa Monica, California.

Kenneth J Pienta (KJ)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, Maryland.
Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.
Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland.

Howard R Soule (HR)

Prostate Cancer Foundation, Santa Monica, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Tumor cell heterogeneity and resistance;...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tumor cell heterogeneity and resistance;...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Tumor cell heterogeneity and resistance;...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumor cell heterogeneity and resistance;...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Tumor cell heterogeneity and resistance;...